Skip to main content

ENANTA PHARMACEUTICALS INC

For the period ended Dec 31, 2024. Filed Feb 12, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2024 · Filed Feb 12, 2025

ENTA$11.22-2.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders' Equity

Accumulated
Additional · Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
SharesAmountCapitalIncome (Loss)DeficitEquity
Balances, September 30, 202421,194$212$451,340$302$(323,040)$128,814
Exercise of stock options11—94——94
Vesting of restricted stock units, net of withholding1281(138)——(137)
Stock-based compensation expense——5,666——5,666
Other comprehensive loss———(331)—(331)
Net loss————(22,290)(22,290)
Balances, December 31, 202421,333$213$456,962$(29)$(345,330)$111,816
Accumulated
Additional · Other · Total
Common Stock · Paid-In · Comprehensive · Accumulated · Stockholders'
SharesAmountCapitalIncome (Loss)DeficitEquity
Balances, September 30, 202321,059$211$424,693$(1,174)$(206,995)$216,735
Vesting of restricted stock units, net of withholding971(184)——(183)
Stock-based compensation expense——8,099——8,099
Other comprehensive income———640—640
Net loss————(33,407)(33,407)
Balances, December 31, 202321,156$212$432,608$(534)$(240,402)191,884
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.